Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bionano Genomics, Inc. (NASDAQ: BNGO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, Bionano submits annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its financial condition, results of operations, risk factors and material corporate events.
Bionano’s recent Forms 8-K include disclosures about quarterly financial results, such as reports for the second and third quarters of 2025, and about capital markets transactions, including a September 2025 public offering of common stock and Series E and Series F warrants. The company has also filed a registration statement on Form S-1 relating to offerings of common stock, pre-funded warrants and warrants, which outlines offering terms, risk factors and use of proceeds.
Through this page, users can review Bionano’s descriptions of its business as a provider of optical genome mapping (OGM) solutions, diagnostic services and software, as well as its discussion of revenue sources, cost structure and liquidity. Filings may also include information on shareholder votes, such as the corrected voting results reported in an 8-K/A filed in June 2025, and details of securities purchase agreements and engagement letters with placement agents for public offerings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify topics such as OGM adoption, consumables and software utilization, capital raises and going concern considerations. Investors can use this resource to track Bionano’s Forms 10-K and 10-Q for comprehensive financial statements, Forms 8-K for event-driven updates, and registration statements for securities offerings, while AI-generated insights assist in understanding the implications of each filing.
Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a small tax-related share disposition. On the vesting of a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 18 shares of common stock at $1.10 per share to cover tax obligations, leaving Chaubey with 644 directly owned shares.
The Principal Accounting Officer of Bionano Genomics, Inc., Mark Adamchak, reported a small tax-related share disposition. On February 15, 2026, 3 shares of common stock were withheld by the company at
Bionano Genomics reported an insider equity transaction involving its General Counsel, Jonathan V. Dixon. On February 15, 2026, 6 shares of common stock were withheld by the company to cover tax obligations tied to a restricted stock unit award vesting, at a price of $1.10 per share. After this tax-withholding disposition, Dixon directly owns 263 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. chief operating officer Mark Oldakowski reported an automatic share disposition related to tax withholding. On shares that vested from a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 20 shares of common stock on February 15, 2026 to cover his tax obligations, at an indicated value of $1.10 per share. After this tax-withholding disposition, Oldakowski directly owned 895 shares of Bionano Genomics common stock. This was not an open-market buy or sell order, but a routine settlement mechanism tied to equity compensation.
Bionano Genomics President and CEO R. Erik Holmlin reported a small tax-related share disposition. On the settlement of a restricted stock unit (RSU) award that vested on February 15, 2026, the issuer withheld 51 shares of common stock at
Bionano Genomics, Inc. received an updated ownership report from Lind Global Fund III and related parties. The reporting group, which includes Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton, reports beneficial ownership of 1,050,000 shares of common stock, representing 9.35% of the outstanding class as of December 31, 2025.
The position consists of 525,000 Series E warrants and 525,000 Series F warrants to purchase common stock. These warrants are subject to a 9.9% beneficial ownership cap, meaning they cannot be exercised if such exercise would push the holders’ ownership above that threshold. The reporting persons certify that the securities were not acquired to change or influence control of Bionano Genomics.
CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 1,129,411 shares of Bionano Genomics, Inc. common stock, representing 9.9% of the class.
The reported position consists of shares issuable upon exercise of warrants, which are subject to 4.99% and 9.99% beneficial ownership limits that restrict further exercises above those thresholds. Bionano had 10,176,000 shares outstanding as of November 5, 2025. The reporting parties certify the holdings were not acquired to change or influence control of the company.
Bionano Genomics, Inc. reported an insider equity award to its Principal Accounting Officer, Mark Adamchak. On February 2, 2026, he received a stock option giving him the right to buy 10,890 shares of common stock at an exercise price of $1.27 per share. The option was granted at no cost and is held directly. According to the filing, 100% of the shares subject to the option vest on the one-year anniversary of the grant date, aligning his compensation more closely with the company’s future share performance.
Bionano Genomics reported an insider equity award for its Chief Medical Officer, Alka Chaubey. On 02/02/2026, Chaubey received a stock option to buy 27,737 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months, beginning on the one-month anniversary of the vesting commencement date, and becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, Chaubey beneficially owns 27,737 derivative securities directly, and the filing does not report any share sales.
Bionano Genomics chief operating officer Mark Oldakowski received a grant of 27,737 stock options on February 2, 2026. The options give him the right to buy Bionano Genomics common stock at an exercise price of $1.27 per share and expire on February 1, 2036.
The award vests in monthly installments over 48 months, starting one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, he beneficially owns 27,737 derivative securities directly.